LANZUL

This brand name is authorized in Estonia, Croatia, Lithuania, Poland, Romania

Active ingredients

The drug LANZUL contains one active pharmaceutical ingredient (API):

1 Lansoprazole UNII 0K5C5T2QPG - LANSOPRAZOLE

Lansoprazole is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H+/K+ ATPase of the parietal cells in the stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid. Read about Lansoprazole

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A02BC03	Lansoprazole	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BC Proton pump inhibitors
Discover more medicines within A02BC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1023679
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-465550599, HR-H-768580684
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1011151, 1022978, 1024456, 1024457, 1024458, 1024459, 1024460, 1024461, 1024462, 1024463, 1024464, 1024465, 1078608, 1079256
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100076891, 100101028
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W03936001